
Whole Exome Sequencing Services
DNA Efficient Coding Variant Identification
Whole Exome Sequencing Services (WES) is a powerful tool in genomic research. It focuses on the protein-regions of the genome. These regions contain the majority of variants which can be related to diseases. Consequently, SeqMatic offers comprehensive exome sequencing services within a CLIA/CAP certified laboratory environment, catering to both research and clinical demands. Furthermore, exome sequencing is used in large scale applications such as population genetics, genetic disease research, and cancer studies.
HIDDEN
HIDDEN
Service Applications of Whole Exome Sequencing
![]() |
![]() |
![]() |
Population Genetics |
Genetic Disease Research |
Cancer Studies |
In population genetics, WES presents advantages such as scalability and enhanced data accuracy through extensive coverage of coding regions. These factors facilitate large-scale genomics, where the obtained sequencing information can be utilized to evaluate medical conditions that have a significant impact on healthcare, like hereditary breast and ovarian cancer syndrome (HBOC), familial hypercholesterolemia (FH), and Lynch syndrome (LS), to name a few examples. | In genetic disease research, WES offers significant advantages for identifying genetic mutations associated with birth defects, developmental delays, and rare Mendelian disorders. By targeting protein-coding regions of the genome as well as untranslated regions (UTRs) and intron-exon boundaries in certain cases, WES is a scalable approach. WES has a higher diagnostic rate compared to traditional molecular tests, such as single gene sequencing, small gene panels, or chromosomal microarrays for rare Mendelian disorders. | In cancer investigations, extensive sequencing information is employed for tumor analysis. WES plays a crucial role in determining patient groups at an elevated risk for specific cancers, as it offers a comprehensive view of genetic anomalies influencing tumor development, such as microsatellite instability and detectable inheritable mutations. As a multifaceted tool, exome sequencing allows for the concurrent observation of diverse genomic alterations in cancerous tissue. Furthermore, depending on research requirements, cancer exome sequencing content can be broadened to encompass untranslated regions and microRNA (miRNA) binding sites. |
Whole exome sequencing (WES) offers an efficient and consistent approach to identifying genetic variants that impact protein sequences. WES is the genomic technique of preference for sequencing all of the protein-coding regions of genes in a genome (known as the exome).
Advantages | Features | Benefits |
Increased possibility for identification of novel diseases | A number of different technologies are available (ie. Agilent SureSelect™) | Eliminates unnecessary diagnostic tests by undergoing exome sequencing |
Targeted analysis for discovery -based studies | World-Class Data quality generated within a CLIA/CAP environment | Enables the identification of genetic mutations related to birth defects and developmental delays |
Commercially available exome panels | Comprehensive services across the entire NGS workflow, from extraction and library preparation to sequencing and bioinformatics | Enables the determination of specific genetic irregularities and the cause of pre-identified issues in a particular protein |
Increased throughput capabilities | Additional insights from samples are available by using our Epigenomics, Spatial Transcriptomics and Histopathology services | Detecting new genetic variations associated with health conditions which can aid future disease diagnosis |
Manageable datasets ready for analysis | Reliable, fast turnaround times available for all sequencing needs |
“SeqMatic exhibits the best in sequencing performance, customer service, and turnaround. My experience in getting several runs completed was an absolute pleasure, and I would recommend SeqMatic to anyone with sequencing needs!”
Customer F.G.
San Francisco, CA
Aldinger, Kimberly A., et al. “Spatial and cell-type transcriptional landscape of human cerebellar development.” Nature neuroscience 24.8 (2021): 1163.
Sifuentes-Dominguez, Luis F., et al. “SCGN deficiency results in colitis susceptibility.” Elife 8 (2019): e49910.
Nair, Anup K., et al. “Generation of Isogenic hiPSCs with Targeted Edits at Multiple Intronic SNPs to Study the Effects of the Type 2 Diabetes Associated KCNQ1 Locus in American Indians.” Cells 11.9 (2022): 1446.
Schupp, Patrick G., et al. “Clarifying the Transcriptional Profiles of Malignant Clones through Multiscale and Multiomic Analysis of Individual Tumors.” bioRxiv (2023): 2023-06.
Find other Research Publications from around the world!
Optimize Your Results
Solutions are custom-made according to research needs




Pre-Submission
Planning & Consultation - Assurance of de-identified sample submission and handling
Sample Submission
Nucleic Acid Extraction - We accept a wide range of sample types
Library Preparation
Library Generation - Amplified cDNA is used for sequence libraries' construction
Sequencing
Different platforms for different data outputs
Data Analysis
Custom Bioinformatics